Skip to main content
All lobbying clients

AIM IMMUNOTECH INC.

Lobbying client · Florida · filed 2025 to 2026

Biopharmaceutical company

$40,000 Reported spend
7 Filings counted
1 Outside firm hired
0 Bills named

Spend is reported income plus in-house expenses across 7 filings. Everything on this page comes from one LDA client record (204543), filed by the registrant listed below.

 Who filed for this client 1

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Reported by year 2 years
  • 2026 $0 3 filings
  • 2025 $40,000 4 filings
 Issues lobbied 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 3
  • Defense, Dept of (DOD) 2
  • HOUSE OF REPRESENTATIVES 2
  • SENATE 2
 Recent filings 7 total
Q3 reportNo activity
BUCHANAN INGERSOLL & ROONEY PC
3rd Quarter 2026 (July 1 - Sep 30) · posted Oct 20, 2026
View → Q2 reportNo activity
BUCHANAN INGERSOLL & ROONEY PC
2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 20, 2026
View → Q1 reportNo activity
BUCHANAN INGERSOLL & ROONEY PC
1st Quarter 2026 (Jan 1 - Mar 31) · posted Apr 20, 2026
View → Q4 reportNo activity
BUCHANAN INGERSOLL & ROONEY PC
4th Quarter 2025 (Oct 1 - Dec 31) · posted Jan 20, 2026
View → Q3 reportNo activity
BUCHANAN INGERSOLL & ROONEY PC
3rd Quarter 2025 (July 1 - Sep 30) · posted Oct 15, 2025
View → Q2 report
BUCHANAN INGERSOLL & ROONEY PC
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 17, 2025
View → Q1 report
BUCHANAN INGERSOLL & ROONEY PC
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $20,000 income · posted Apr 2, 2025
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem